healthpharma
While Eli Lilly & Co (NYSE: LLY) has captured the spotlight in 2024 due to the soaring demand for its weight-loss drug, investors may want to turn their attention to another pharmaceutical giant: Johnson & Johnson (NYSE: JNJ). With its undervalued stock, robust pipeline, and industry-leading sales, Johnson & Johnson is poised to be a strong contender for joining the exclusive trillion-dollar club over the next decade. Eli Lilly has become a favorite among investors, driven by its dominance in the obesity market—a sector expected to grow at a compound annual growth rate (CAGR) of 43.73% over th...
Invezz
Cathie Wood, a prominent advocate for innovative technologies, is making a bold bet on artificial intelligence with her latest investment in Tempus AI Inc. (NASDAQ: TEM). Known for her strategic focus on transformative technologies, Wood’s decision to heavily invest in Tempus reflects her confidence in the company’s potential within the burgeoning AI health-tech sector. Tempus stock, which debuted on the Nasdaq Stock Exchange in June at around $40, has surged over 50% since its initial offering, underscoring growing investor enthusiasm. Wood allocates $1.5 million to Tempus AIWood has recently...
Invezz
Eli Lilly & Co (NYSE: LLY) has made a groundbreaking revelation that its weight-loss drug, Tirzepatide, reduces the risk of developing type 2 diabetes by an astonishing 94% in overweight adults with pre-diabetes. Based on long-term clinical trials, this discovery solidifies the drug’s potential as a game-changer in the fight against diabetes, a condition affecting millions globally. With these results, Eli Lilly’s stock surged nearly 2% on Tuesday, pushing the company closer to a historic $1 trillion valuation. The study, which involved over 1,000 adults, revealed that those who received the h...
Invezz
Cingulate Inc (NASDAQ: CING), a biopharmaceutical company that focuses primarily on innovative treatments for Attention Deficit Hyperactivity Disorder (ADHD) is having an extraordinary day. Shares of the $10 million company based out of Kansas opened a whopping 115% up on Friday as investors cheered a European patent it secured for CTx-1301 – its lead asset for the treatment of ADHD. The stock is rallying sharply as the aforementioned patent is a significant milestone in the company’s global expansion strategy. Cingulate stock is now on track to close this week with a total of more than 400% g...
Invezz
Shares of Bavarian Nordic, a Danish vaccine manufacturer, surged over 15% on Thursday following the World Health Organization’s (WHO) declaration of Mpox as a public health emergency. This announcement has drawn significant attention to the Hellerup-based company, which, alongside Emergent BioSolutions Inc., is one of the only two firms with a vaccine endorsed by the Centers for Disease Control and Prevention (CDC) for combating the Mpox (also known as monkeypox) virus. Emergent BioSolutions also saw a stock rise of over 10% in response. The WHO’s declaration reverberated globally, particularl...
Invezz
The World Health Organisation on Wednesday declared the upsurge of monkeypox virus or ‘Mpox’ in Africa a public health emergency of international concern (PHEIC), stating it had the potential to spread across countries in Africa and possibly outside the continent. The virus originated in the Democratic Republic of Congo (DRC) and, in the last month, there have been 100 laboratory-confirmed cases reported in four countries—Burundi, Kenya, Rwanda, and Uganda—that had not previously reported this illness. Experts believe the real number of cases could be higher as a large proportion of clinically...
Invezz
The global online counseling market, valued at $2.35 billion in 2023, is on track to more than double, reaching $4.14 billion by 2032. This growth, reflecting a compound annual growth rate (CAGR) of 6.52%, is driven by rising consumer awareness, technological advancements, and increasing smartphone adoption. Enhanced internet infrastructure and growing mental health issues, such as anxiety and depression, further fuel this expansion. Benefits of online counseling Online counseling offers significant advantages, including accessibility, affordability, and convenience. These benefits are pivotal...
Invezz
VSee Health Inc (NASDAQ: VSEE) saw its stock nearly triple on Friday, fueled by an exciting new partnership with Ava Robotics. This collaboration aims to enhance intensive care units (ICUs) by integrating VSee’s telehealth technology into Ava’s robotic systems, allowing for remote, personalized patient care. The newly announced partnership will see VSee’s software embedded into Ava robots, significantly enhancing telehealth services. This integration is set to extend advanced medical care from large hospitals to regional and smaller intensive care units across the United States, according to a...
Invezz
Teladoc Health (NASDAQ: TDOC) stock price continued its downfall, making it one of the worst-performing companies in Wall Street. It crashed by over 17.30% in the pre-market session after falling by 3% on Wednesday. The fall from grace continuesTeladoc, the biggest telehealth company in the US, has had a remarkable fall from grace in the past few years. Its stock dropped from its all-time high of $307.40 in 2021 to just $7 today. Along the way, its market cap has fallen from over $50 billion to just $1.5 billion. Teladoc Health has had a strong fall from grace after doing phenomenally well dur...
Invezz
Vaccinex Inc (NASDAQ: VCNX) tanked an alarming 40% on Wednesday despite it reporting positive early-stage results for its Alzheimer’s treatment. The biotechnology company said its SIGNAL-AD trial established its pepinemab antibody as well-tolerated by patients of AD. A total of 16 clinical sites participated in the study, none of which reported any treatment-related serious adverse event. Previous trials have already established pepinemab as well-tolerated in patients of multiple sclerosis and Huntington’s disease as well. Eric Siemers – the principal investigator presented the topline results...
Invezz
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら